Andrew A. Lane, Md, Phd, Shares Outcomes From The Phase 2 Study Of Sl-401 In Patients With Bpdcn

Andrew A. Lane, MD, PhD, shares outcomes from the phase 2 study of SL-401 in patients with BPDCN

Andrew Lane, MD, PhD, describes the efficacy outcomes of SL-401 consolidation therapy in AML

Results of Phase II multicenter trial of SL-401 in BPDCN

VJHemOnc – Video Journal of Hematology & HemOnc

Dr. Lane on Identification of BPDCN

Dr. Pemmaraju on SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasms

SL-401: An Encouraging Option for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm

American Society of Hematology

SL401 in patients with rare neoplasm

Tagraxofusp for BPDCN gives encouraging results

VJHemOnc – Video Journal of Hematology & HemOnc

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) - Diagnosis and Treatment

Leukemia & Lymphoma Society

Positive results for IL-3R inhibition in BPDCN

VJHemOnc – Video Journal of Hematology & HemOnc

Dr. Lane on leukemia treatment | Dana-Farber Cancer Institute

Dana-Farber Cancer Institute

Andrew Lane, MD, PhD, on minimal residual disease and AML treatment decisions

Dr. Patnaik on Activity of SL-401 in Chronic Myelomonocytic Leukemia

Behind the Mystery: Understanding Blastic Plasmacytoid Dendritic Cell Neoplasm | The Balancing Act

The Balancing Act

Andrew Lane, MD, PhD, on treatment approaches when managing frail AML patients

Naveen Pemmaraju, MD: Tagraxofusp for BPDCN

Estimating long-term outcomes in patients with cHL using an oncology simulation model

VJHemOnc – Video Journal of Hematology & HemOnc

Local gym rallies around young trainer diagnosed with rare cancer

KRQE

VEITHsymposium™ 2019: ALTO (Ovation) Endograft System — Prof Sean P Lyden

Radcliffe Cardiology

Investigating Intrinsic and Extrinsic Factors Associated with ALS

Les Turner ALS Foundation